|
GMPR2 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.449870E-04 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.599400E-04 |
| Normal-vs-Stage2 |
7.757400E-01 |
| Normal-vs-Stage3 |
2.52800000000164E-06 |
| Normal-vs-Stage4 |
6.91530000040963E-07 |
| Stage1-vs-Stage2 |
2.059900E-02 |
| Stage1-vs-Stage3 |
1.562400E-02 |
| Stage1-vs-Stage4 |
5.279600E-03 |
| Stage2-vs-Stage3 |
1.981890E-04 |
| Stage2-vs-Stage4 |
2.243400E-04 |
| Stage3-vs-Stage4 |
6.008600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.225100E-04 |
| Normal-vs-AfricanAmerican |
6.345600E-02 |
| Normal-vs-Asian |
2.427500E-04 |
| Caucasian-vs-AfricanAmerican |
4.945200E-01 |
| Caucasian-vs-Asian |
8.000400E-01 |
| AfricanAmerican-vs-Asian |
4.379800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.215460E-03 |
| Normal-vs-Female |
1.559170E-04 |
| Male-vs-Female |
9.637800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.367300E-04 |
| Normal-vs-Age(41-60Yrs) |
1.264730E-03 |
| Normal-vs-Age(61-80Yrs) |
8.447500E-04 |
| Normal-vs-Age(81-100Yrs) |
3.335700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.065600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.161200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.001610E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.016600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.524410E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.303600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.88200999999832E-05 |
| Classical-VS-Follicular |
1.482160E-01 |
| Classical-VS-Other |
6.503000E-01 |
| Classical-VS-Normal |
8.38560000000488E-05 |
| Tall-VS-Follicular |
1.6099499999922E-05 |
| Tall-VS-Other |
1.212180E-01 |
| Tall-VS-Normal |
1.93189997332865E-09 |
| Follicular-VS-Other |
9.749200E-01 |
| Follicular-VS-Normal |
9.120500E-02 |
| Other-VS-Normal |
4.236400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.464700E-03 |
| Normal-vs-N1 |
1.24280000002308E-06 |
| N0-vs-N1 |
5.940100E-03 |
|
|
